Abstract
BackgroundPlatelet-cancer cell interactions play a key role in successful haematogenous metastasis. Disseminated malignancy is the leading cause of death among ovarian cancer patients. It is unknown why different ovarian cancers have different metastatic phenotypes. To investigate if platelet-cancer cell interactions play a role, we characterized the response of ovarian cancer cell lines to platelets both functionally and at a molecular level.MethodsCell lines 59 M and SK-OV-3 were used as in vitro model systems of metastatic ovarian cancer. Platelet cloaking of each cell line was quantified by flow cytometry. Matrigel invasion chamber assays were used to assess the invasive capacity of the cell lines. The induction of an EMT was assessed by morphology analysis and by gene expression analysis of a panel of 11 EMT markers using TaqMan RT-PCR.ResultsSK-OV-3 cells adhered to and activated more platelets than 59 M cells (p = 0.0333). Platelets significantly promoted the ability of only SK-OV-3 cells to invade (p ≤ 0.0001). Morphology and transcritpome analysis indicated that platelets induce an epithelial-to-mesenchymal transition phenotype in both cells lines, with a more exaggerated response in SK-OV-3 cells. Next, we investigated if antiplatelet agents could abrogate the platelet-induced aggressive phenotype in SK-OV-3 cells. Both aspirin (p ≤ 0.05) and 2-methylthioadenosine 5′-monophosphate triethylammonium salt hydrate (P2Y12 inhibitor; p ≤ 0.01) significantly decreased their invasion capacity, and effectively reverted invasion to levels comparable to SK-OV-3 cells alone.ConclusionWhile there is increasing evidence for the cancer-protective effect of aspirin, this study suggests P2Y12 inhibition may also play a role. Understanding these complex interactions between platelets and cancer cells could ultimately allow the establishment of therapies tailored to inhibiting metastasis, thus significantly reducing cancer morbidity.
Highlights
Platelet-cancer cell interactions play a key role in successful haematogenous metastasis
Since the antiplatelet agent aspirin is associated with a reduce risk of death and distant metastasis in cancer patients [25,26,27] including those with ovarian cancer [28], we investigated the effect of aspirin and the antiplatelet P2Y12 blocker, 2methylthioadenosine 5′-monophosphate triethylammonium salt hydrate (2MeSAMP), on the platelet cancer cell interaction
There was a significant increase in expression of the mesenchymal markers, vimentin (VIM) and plasminogen activator inhibitor-1 (PAI-1; Serpine1), while there was a significant decrease in the expression of the epithelial marker E-cadherin (CDH1) (Fig. 2b)
Summary
Platelet-cancer cell interactions play a key role in successful haematogenous metastasis. Disseminated malignancy is the leading cause of death among ovarian cancer patients. It is unknown why different ovarian cancers have different metastatic phenotypes. A growing body of evidence suggests that platelets have a key role in successful haematogenous metastasis. The formation of tumour cell-induced platelet aggregates (TCIPA) facilitate immune evasion [1, 2], provide angiogenic and growth factors [3, 4], and promote microvascular arrest of at distant sites [5,6,7]. A recent study demonstrated a direct proliferative effect of platelets on ovarian cancer cells mediated via
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
